Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of Anti-Iduronate 2-Sulfatase Antibodies in Patients with Mucopolysaccharidosis Type II Treated with Enzyme Replacement Therapy.

The Journal of pediatrics - 1 Sept 2022

Vollebregt Audrey A M, Hoogeveen-Westerveld Marianne, Ruijter George J, van den Hout Hannerieke, Oussoren Esmee, van der Ploeg Ans T, Pijnappel W W M Pim

Abstract excerpt

OBJECTIVE: To assess the relationship between anti-Iduronate 2-sulfatase (IDS) antibodies, IDS genotypes, phenotypes and their impact in patients with enzyme replacement therapy (ERT)-treated Mucopolysaccharidosis type II. STUDY DESIGN: Dutch patients treated with ERT were analyzed in this observational cohort study. Antibody titers were determined by enzyme-linked immunosorbent assay. Neutralizing effects were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to Enzyme Replacement Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycosaminoglycans

Share to Iduronate Sulfatase

Share to Mucopolysaccharidosis II

Share to Phenotype

Source

Identifiers

PMID: 35568060
DOI: 10.1016/j.jpeds.2022.05.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of Anti-Iduronate 2-Sulfatase Antibodies in Patients with Mucopolysaccharidosis Type II Treated with Enzyme Replacement Therapy.PMID 35568060Read ↗

The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.Semantic proximity Read ↗

Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase.Semantic proximity Read ↗

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).Semantic proximity Read ↗

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.Semantic proximity Read ↗

Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler's syndrome after pharmacological enzyme replacement therapySemantic proximity Read ↗

Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome.Semantic proximity Read ↗

Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype.Semantic proximity Read ↗

Analysis of N-acetylgalactosamine-4-sulfatase protein and kinetics in mucopolysaccharidosis type VI patients.Semantic proximity Read ↗

Iduronate-2-sulphatase protein detection in plasma from mucopolysaccharidosis type II patients.Semantic proximity Read ↗

Enzyme replacement therapy in a murine model of Morquio A syndromeSemantic proximity Read ↗

Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: comparison in two siblings.Semantic proximity Read ↗

Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.